Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles


Jang-Yang Chang, M.D.

Distinguished Investigator and Attending Physician; Director
National Institute of Cancer Research
jychang@nhri.org.tw

EDUCATION

M.D., Department of Medicine, National Defense Medical Center, Taiwan, 1982

PROFESSIONAL EXPERIENCES

  • Distinguished Investigator and Attending Physician; Director, National Institute of Cancer Research, National Health Research Institutes, Taiwan

  • Adjunct Professor of Internal Medicine, National Defense Medical Center, Taiwan

  • Chief of Medical Oncology, Tri-ServiceGeneralHospital, National Defense Medical Center, Taiwan

  • Visiting Scholar, Department of Pharmacology, Yale Medical School, USA
  • RESEARCH INTERESTS

    Dr. Chang's research interests focus on three fields; (1) study the mechanisms of drug resistance, especially camptothecins, and the relationship between CPT-resistance and DNA repair; (2) anti-cancer drug development, focusing on topoisomerase I and II and tubulin inhibitors; (3) regulation of DNA repair enzyme, MGMT.

    RESEARCH ACTIVITIES & ACCOMPLISHMENTS

    Recently, they have first demonstrated that DNA repair enzyme, MGMT, is able to modulate the cytotoxicity of topoisomerase I inhibitor, CPT. They also found hormonal agent, tamoxifen, can accelerate degradation of MGMT. This finding provides a strong rationale to develop combined chemohormonal therapy for patient with cancers Moreover, they have synthesized a series of antitubulin compounds, some of these compounds exhibit potent antitumor activity in vitro and in vivo (J Med Cem. 2004; Cancer Research 2004; J Med Chem 2006). US patent was granted. Phase I clinical trial is going to start.
    with cancers Moreover, they have synthesized a series of antitubulin compounds, some of these compounds exhibit potent antitumor activity in vitro and in vivo (J Med Cem. 2004; Cancer Research 2004; J Med Chem 2006). US patent was granted. Phase I clinical trial is going to start.

    HONORS & AWARDS

  • Outstanding Poster Award, The 13rd Annual Taiwan Joint Cancer Conference, 2008

  • Outstanding Poster Award, The 12nd Annual Taiwan Joint Cancer Conference, 2007

  • Outstanding Poster Award, The 11th Annual Taiwan Joint Cancer Conference, 2006

  • Outstanding Poster Award, The 10th Annual Taiwan Joint Cancer Conference, 2005

  • Outstanding research award of Chien-Ten Hsu Cancer Research Foundation, 2005

  • Outstanding Poster award, The 9th Annual Taiwan Joint Cancer Conference, 2004

  • Outstanding Poster award, The 8th Annual Taiwan Joint Cancer Conference, 2003

  • Outstanding Poster award, The 6th Annual Taiwan Joint Cancer Conference, 2001

  • SELECTED PUBLICATIONS

  • Juang SH, Lung CC, Hsu PF, Hseu KS, Li YC, Hong PC, Shiah HS, Kuo CC, Huang CW, Wang YC, Huang LY, Chen TS , Fong Chen SF, Fu KC , HL Hsu, Lin MJ, Chang CJ, Chou KM, and Chang JY*. D-501036, a Novel Selenophene-based Triheterocycle Derivative, Exhibits Potent in vitro and in vivo Anti-tumoral Activity Which Involves DNA damage and ATM activation. Molecular Cancer Therapeutics 6: 193-202, 2007

  • Chang JY, Hsieh HP, Chang CY, HsuKS, Chiang YF, Chen CM, Kuo CC and Liou JP*. 7-Aroyl-aminoidoline-1-sulfonamides as a novel class of antitubulin agents. J Med Chem, 49:6656-6659, 2006.

  • Chang JY, Yang MF, Chang CY, Chen CM, Kuo CC and Liou JP*. 2-amino and 2??-aminocombrestatins as potent antitubulin agents. J Med Chem, 49:6412-6415, 2006.

  • Kuo CC, Liu JF and Chang JY*. DNA repair enzyme,O6-methylguanine methyltransferase, modulates the cytotoxicity of CPT-derived topoisomerase I inhibitors. Journal of Pharmacology and Experimental Therapeutics, 316(2): 946-954, 2006.

  • Kuo, CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT and Chang JY*. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Research, 64:4621-4628, 2004.

  • Chang JY*, Chang CY, Kuo CC, Chen LT, Wein YS and Kuo YH. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Dansen), with antimitotic activity in multidrug-sensitive and-resistant human tumor cells. Molecular Pharmacology, 65(1): 77-84, 2004.

  • Chang JY*, Liu JF, Jung SH, Liu TW and Chen LT. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res, 62:3716-3721, 2002.
  • PATENT

    • DB67-ROC patent

    • US patent US20030195244A1 "New indole compounds as anticancer agents"

    • US patent 6821983 B2; ROC 1-246508 "5-(9-acridinylamino)-toluidine compounds"

    • US 5332811"Etoposide analogs"

    • US20030195244A1 "Indole compounds" (Granted) Hsieh HP, Liou JP, Chang JY, Chang CW.

    • Hsieh HP, Chao YS, Liou JP, Chang JY, Tung YS: US: (Granted)

    • EP1506960A1 "Indole compounds" (Pending) Hsieh HP, Liou JP, Chang JY, Chang CW.

    • CA2437104AA "Indole compounds" (Pending) Hsieh HP, Liou JP, Chang JY, Chang CW.

    • TW200301110 "Indole compounds" (Pending) Hsieh HP, Liou JP, Chang JY, Chang CW.